Dextenza effectively controls inflammation after iStent or Hydrus insertion during cataract surgery

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-09 14:30 GMT   |   Update On 2022-09-10 09:09 GMT

Dextenza effectively controls inflammation after iStent or Hydrus insertion during cataract surgery suggests a recent study published in the Journal of Glaucoma Using an intracanalicular dexamethasone insert or topical prednisolone following iStent and Hydrus surgery provided similar short-term control of postoperative inflammation. The purpose of this study was to...

Login or Register to read the full article

Dextenza effectively controls inflammation after iStent or Hydrus insertion during cataract surgery suggests a recent study published in the Journal of Glaucoma

Using an intracanalicular dexamethasone insert or topical prednisolone following iStent and Hydrus surgery provided similar short-term control of postoperative inflammation.

The purpose of this study was to compare postoperative inflammation in patients who received an intracanalicular dexamethasone insert or topical prednisolone after iStent or Hydrus insertion during cataract surgery.

Patients receiving a dexamethasone insert after iStent or Hydrus insertion were included and compared with age-matched controls who received topical prednisolone. Preoperative data were recorded. Postoperative inflammatory cell and the proportion of patients with zero anterior chamber cells was recorded at month 1. Postoperative intraocular pressure (IOP) and rate of cystoid macular edema were recorded at months 1 and 3.

Results:

  • Forty eyes receiving topical prednisolone were compared with 35 eyes receiving a dexamethasone insert after iStent or Hydrus insertion.
  • The mean postoperative inflammatory cell for the topical group at month 1 was 0.2±0.3, and the dexamethasone group, 0.3±0.5 (P=0.816). Overall, 70% of patients in the topical group had zero anterior chamber cell at postoperative month 1 compared with 75.8% in the dexamethasone group (P=0.583).
  • The mean preoperative IOP for the topical group was 18.8±5.5 and the dexamethasone group was 17.1±4.1 (P=0.064).
  • Mean postoperative IOP for the topical group at months 1 and 3 was 17.6±6.4 and 15.1±3.1, respectively and the dexamethasone group, 17.5±4.8 and 15.0±3.4, respectively (P=0.772 and 0.884).
  • One patient developed cystoid macular edema in each group.

Thus, there was no statistically significant difference in the proportion of patients who had zero anterior chamber cell at postoperative month 1 between groups receiving intracanalicular dexamethasone insert or topical prednisolone.

Reference:

Jackson, Kevin J. MD*; Akrobetu, Dennis BS†; Guduru, Abhilash MD*; Herndon, Leon W. MD*. Intracanalicular Dexamethasone Insert or Topical Prednisolone Following iStent and Hydrus Surgery for Glaucoma. Journal of Glaucoma: August 2022 - Volume 31 - Issue 8 - p 694-699 doi: 10.1097/IJG.0000000000002037

Keywords:

Dextenza, effectively, controls, inflammation, iStent, or Hydrus, insertion, cataract surgery, Jackson, Kevin J, Akrobetu, Dennis; Guduru, Abhilash; Herndon, Leon W, Journal of Glaucoma

Tags:    
Article Source : Journal of Glaucoma

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News